AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00580593 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham-NIPPV
Description: a sham-device
Study NCT04969458 — intervention group
Intervention type: OTHER
Intervention: survey application
Description: Data collection tools used in the study;~* Clinic and Demographic Evaluation Form~* Oswestry Low Back Pain Disability Index (ODI)~* Patterns of Activity Measure Pain (POAM-P)~* Roland-Morris Disability Questionnaire (RMDQ)~* Hospital Anxiety and Depression Scale (HADS)~* Graded Chronic Pain Scale Version 2.0 (GCPS 2.0)
Study NCT00712270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
Study NCT00712270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
Study NCT02020304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined spinal epidural
Description: Combined Spinal Epidural
Study NCT02020304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined spinal epidural
Description: Combined Spinal Epidural
Study NCT02467660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Using study-provided iPod device to listen to guided meditations daily
Study NCT02467660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health & Wellness Education
Description: Using study-provided iPod device to listen to educational podcasts daily
Study NCT02295631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView VivaSight SL
Description: ETI with ETView VivaSight SL
Study NCT00106119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liothyronine and Levothyroxine
Description: Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
Study NCT02364245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinect
Description: Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
Study NCT05187572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group intervention
Description: This intervention was developed during 14 sessions, held twice a week, with a duration of 45 to 60 minutes each. The sessions were developed as group-based interventions, facilitated by a leader and a co-leader from each community institution.
Study NCT00836524 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound
Description: 4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
Study NCT01775800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment modification
Study NCT02485067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THVD-201
Description: Combination of Tolterodine 2mg and Pilocarpine 9mg
Study NCT02485067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THVD-201
Description: Combination of Tolterodine 2mg and Pilocarpine 9mg
Study NCT02485067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(For THVD-201)
Study NCT02485067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detrusitol 2mg tablet
Description: Tolterodine 2mg
Study NCT02485067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(For Detrusitol 2mg tablet)
Study NCT01165294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
Study NCT01165294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
Study NCT02388672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: decaffeinated coffee
Description: Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)
Study NCT02388672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: decaffeinated coffee
Description: Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)
Study NCT02388672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chlorogenic acid
Description: Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)
Study NCT02388672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: chlorogenic acid
Description: Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)
Study NCT02388672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green coffee bean extract supplement
Description: Decaffeinated coffee together with green coffee bean extract supplement (560mg; high-CGA)
Study NCT02388672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Decaffeinated coffee with placebo capsules as control group for green coffee bean extract supplement (224mg; low-CGA)
Study NCT03954704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalutrafusp alfa
Description: Administered intravenously
Study NCT03954704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 Regimen
Description: Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin
Study NCT00773630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: 100 mg Cilostazol
Study NCT00773630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: 100 mg Cilostazol
Study NCT04810637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-I7
Description: Recombinant human interleukin-7 hybrid Fc
Study NCT04810637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GX-I7
Description: Recombinant human interleukin-7 hybrid Fc
Study NCT00996541 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: STRIVE family intervention
Description: Adolescent and parent attend a 5-session family-oriented cognitive-behavioral intervention aimed at giving runaway youths and their parents the tools to effectively deal with conflict.
Study NCT00996541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRIVE family intervention
Description: Adolescent and parent attend a 5-session family-oriented cognitive-behavioral intervention aimed at giving runaway youths and their parents the tools to effectively deal with conflict.
Study NCT02279160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD811
Study NCT02279160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01100658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: 1 capsule each day for 1 week, .3 mg/kg dose.
Study NCT01100658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day for 1 week.
Study NCT01572636 — intervention group
Intervention type: DRUG
Intervention: Laronidase
Description: Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
Study NCT01492816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization
Description: The proposed study seeks to continue C2P community mobilization efforts that have developed coalitions that plan for and bring about structural changes for purposes of reducing Human Immunodeficiency Virus (HIV) incidence and prevalence among youth in targeted communities at nine sites. Earlier phases of C2P have been outlined in ATN Protocols 016a, 016b, 040/040b. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action (accomplished in an earlier phase of C2P); coalitions establishing a shared vision and mission; development of a strategic plan focused on structural changes to reduce risks associated with HIV; process documentation; and feedback as technical assistance to the coalitions.
Study NCT00410345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone
Study NCT00410345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Study NCT00820690 — intervention group
Intervention type: DRUG
Intervention: cyclophosphamide
Description: 4 cycles AC: cyclophosphamide 600mg/m2
Study NCT02405884 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kowa HA-2 Perkins applanation tonometer.
Description: Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
Study NCT02816411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk protein isolate
Description: Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water.~Placebo consisted of 365 ml water, 125 ml sugar-free cordial and 2g of low-calorie glucose/dextrose powder.
Study NCT02816411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
Study NCT04012151 — intervention group
Intervention type: OTHER
Intervention: Physical measurement
Description: Parturients of gestational week >= 32 weeks will have their arms and fingers measured to generate the conicity index.
Study NCT04012151 — intervention group
Intervention type: OTHER
Intervention: Cuff size fitting
Description: Fit on arm cuff and finger cuff as selected by investigators based on the measurement.
Study NCT00820690 — intervention group
Intervention type: DRUG
Intervention: paclitaxel
Description: 4 cycles T: paclitaxel 175mg/m2 after 4 AC
Study NCT01899001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants will receive weekly, 30 minute sessions with a CBT-trained clinical psychologist for the first 8 weeks. Briefly, the purpose of CBT is to treat mood and associated anxiety disorders by changing dysfunctional thoughts that lead to negative mood states and maladaptive behaviors. Through the use of Socratic questioning, the therapist challenges the patient to observe the relationship between thoughts and feelings and to question the underlying beliefs that perpetuate negative affect. Ultimately, patients learns to recognize maladaptive automatic thoughts and develop a more rational and balanced way of thinking about themselves and the world around them.
Study NCT01899001 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
Study NCT01899001 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrition Counseling
Description: All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
Study NCT01477073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH-GEX™
Study NCT01477073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Study NCT01477073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: urinary FSH
Study NCT01477073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01525108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self monitoring of blood pressure
Description: Electronic blood pressure device is provided for patients and he/she will be trained to measure blood pressure at home once daily(same time each day). A logbook is also provided to document the daily blood pressure level.
Study NCT01525108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Four visits to the physician's office at 4th, 12th, 24th week in the study period with usual advice giving practice of the staff. At the end of the trial period, an electronic blood pressure device will be given to each patient in this arm.
Study NCT01528436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Infusion
Description: The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
Study NCT01528436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Umbilical Cord Blood
Description: Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed.
Study NCT01528436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
Study NCT01528436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
Study NCT01365091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/metformin fixed-dose combination (FDC)
Description: Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
Study NCT01365091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablet, oral, 5 mg, once on Day 1 only, 1 day
Study NCT00739908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX157 (TriRima)
Description: Six capsules administered three times a day for six weeks.
Study NCT00739908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six capsules administered three times a day for six weeks.
Study NCT01365091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin extended-release (XR)
Description: Tablet, oral, 500 mg, once on Day 1 only, 1 day
Study NCT01365091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin/Metformin FDC
Description: Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
Study NCT01365091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet, oral, 1000 mg, once on Day 1 only, 1 day
Study NCT00592176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local injection of bevacizumab
Description: Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
Study NCT00472043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDT with Metvix 160 mg/g cream
Study NCT00472043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01404078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose Polycap
Description: Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
Study NCT03946644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EVLA with keeping of securuty distance
Description: The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
Study NCT03946644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVLA without keeping a distance
Description: The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
Study NCT02352090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol / dienogest
Description: One tablet orally for 9 weeks, continuous use
Study NCT02352090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate / dienogest
Description: One tablet orally for 9 weeks, continuous use
Study NCT02352090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest
Description: One tablet orally for 9 weeks, continuous use
Study NCT03828864 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Shortwave Therapy
Description: Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
Study NCT03828864 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pulsed Shortwave Therapy
Description: Placebo Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
Study NCT04344015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Plasma Donation
Description: Previously infected COVID-19 patients will be recruited to donate convalescent plasma.
Study NCT00820690 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.~The oncoplastic surgery rate will be reported
Study NCT00729651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium (+) cholecalciferol
Description: Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
Study NCT02364245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional OT(30 Mins)
Description: Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
Study NCT00729651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Alendronate sodium (Fosamax)
Description: Alendronate sodium; tablet, once weekly, for 16 weeks
Study NCT00729651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparator: Calcium
Description: 500 mg oral tablet calcium once daily, for 16 weeks
Study NCT00729651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Calcium
Description: 500 mg oral tablet calcium once daily, for 16 weeks
Study NCT04418453 — intervention group
Intervention type: OTHER
Intervention: Integration of telemedicine for MOUD in primary care
Description: Patients with opioid use disorder in rural primary care settings may be referred to receive telemedicine for medication treatment for opioid use disorder
Study NCT01119391 — intervention group
Intervention type: BEHAVIORAL
Intervention: There was no intervention; this was a survey only study
Description: There was no intervention; this was a survey only study
Study NCT02399826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Provision of an offloading cam walker or cast boot, may also convert to total contact cast and add felt or foam to supplement